Surpass (Ankylosing Spondylitis)

This Surpass research study is sponsored by the pharmaceutical company named Novartis. The purpose of the study is to compare the effects of secukinumab and GP2017 (adalimumab biosimilar) on the progression of structural changes to the spine in subjects with AS. Data from this study may be used to support the addition of wording in the Cosentyx® product label regarding a potential benefit on spinal structural changes based on radiographic (X-ray) findings.

Will have spinal xrays at beginning, middle and end of trial.

We will provide physical exams, lab work and the study medication.